Targets › TOPOISOMERASE
2 programs from 2 companies in 3 trials: 3 Phase 3; Infectious disease, Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on TOPOISOMERASE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Huashan Hospital | Levofloxacin DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRA, TOPOISOMERASE | Phase 3 | Multidrug Resistant Tuberculosis; Drug-resistant Tuberculosis | Dec 2026 |
| University of Sydney | Bleomycin Sulfate DNA damage induction via bleomycin-metal complex formation and strand breaking | TOPOISOMERASE | Phase 3 | Germ Cell Tumor | Dec 2029 |
Multidrug Resistant Tuberculosis (1) Drug-resistant Tuberculosis (1) Germ Cell Tumor (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.